CBLB ablation with CRISPR/Cas9 enhances cytotoxicity of human placental stem cell-derived NK cells for cancer immunotherapy

Xuan Guo, Tanel Mahlaköiv , Qian Ye, Srinivas Somanchi, Shuyang He, Hemlata Rana, Andrea DiFiglia, Joseph Gleason, William van der Touw, Robert Hariri, Xiaokui Zhang

To cite: Guo X, Mahlaköiv T, Ye Q, et al. *CBLB* ablation with CRISPR/Cas9 enhances cytotoxicity of human placental stem cell-derived NK cells for cancer immunotherapy. *Journal for ImmunoTherapy of Cancer* 2021;9:e001975. doi:10.1136/jitc-2020-001975

► Additional material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/jitc-2020-001975>).

XG and TM contributed equally.

Accepted 28 January 2021

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Cellularity Inc, Florham Park, New Jersey, USA

Correspondence to

Dr Xiaokui Zhang;
xiaokui.zhang@cellularity.com

ABSTRACT

Background Tumors often develop resistance to surveillance by endogenous immune cells, which include natural killer (NK) cells. Ex vivo activated and/or expanded NK cells demonstrate cytotoxicity against various tumor cells and are promising therapeutics for adoptive cancer immunotherapy. Genetic modification can further enhance NK effector cell activity or activation sensitization. Here, we evaluated the effect of the genetic deletion of ubiquitin ligase Casitas B-lineage lymphoma pro-oncogene-b (*CBLB*), a negative regulator of lymphocyte activity, on placental CD34⁺ cell-derived NK (PNK) cell cytotoxicity against tumor cells.

Methods Using CRISPR/Cas9 technology, *CBLB* was knocked out in placenta-derived CD34⁺ hematopoietic stem cells, followed by differentiation into PNK cells. Cell expansion, phenotype and cytotoxicity against tumor cells were characterized in vitro. The antitumor efficacy of *CBLB* knockout (KO) PNK cells was tested in an acute myeloid leukemia (HL-60) tumor model in NOD-*scid* IL2R gamma^{null} (NSG) mice. PNK cell persistence, biodistribution, proliferation, phenotype and antitumor activity were evaluated.

Results 94% of *CBLB* KO efficacy was achieved using CRISPR/Cas9 gene editing technology. *CBLB* KO placental CD34⁺ cells differentiated into PNK cells with high cell yield and >90% purity determined by CD56⁺ CD3⁺ cell identity. Ablation of *CBLB* did not impact cell proliferation, NK cell differentiation or phenotypical characteristics of PNK cells. When compared with the unmodified PNK control, *CBLB* KO PNK cells exhibited higher cytotoxicity against a range of liquid and solid tumor cell lines in vitro. On infusion into busulfan-conditioned NSG mice, *CBLB* KO PNK cells showed in vivo proliferation and maturation as evidenced by increased expression of CD16, killer Ig-like receptors and NKG2A over 3 weeks. Additionally, *CBLB* KO PNK cells showed greater antitumor activity in a disseminated HL60-luciferase mouse model compared with unmodified PNK cells.

Conclusion *CBLB* ablation increased PNK cell effector function and proliferative capacity compared with non-modified PNK cells. These data suggest that targeting *CBLB* may offer therapeutic advantages via enhancing antitumor activities of NK cell therapies.

INTRODUCTION

Recent years have shown major advancements in the development and successful application of immunotherapies for cancer. Natural killer (NK) cells are key effector cells in cancer immunosurveillance and viral infections that use an array of receptors to distinguish between malignant and healthy cells, and mediate target cell killing. NK cells recognize universal stress ligands on tumor cells and do not elicit graft-versus-host disease,¹ making them an attractive modality for developing off-the-shelf allogeneic cell therapies for treating cancer. Ex vivo expansion, activation, and novel genetic modification techniques, such as the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), can increase the antitumor activity of NK cells by overcoming resistance of tumor cells, increasing cytolytic activity, or promoting persistence and homing to tumor tissue.^{1 2}

Antitumor efficacy of NK cells varies against different tumors, and it is driven by variability in the expression of ligands for NK activation or inhibition.³ Significant efforts to enhance anti-tumor responses of NK cells center around shifting the balance of signaling in favor of targeted activation, such as expression of chimeric antigen receptors (CARs) against various tumor antigens: CD19, CD20, CS1, CD138 and Her2.^{4–14} Alternatively, blockade of inhibitory receptors can lower the threshold for activation. For example, blocking Ly49 with an antibody was shown to improve antitumor function of murine NK cells.^{15 16} In a human NK cell line NK-92, blocking the inhibitory receptors KIR3DL1 and KIR2DL1 improved antibody-dependent cellular cytotoxicity in combination with

rituximab against CD20-expressing B-cell lymphoma.¹⁷ Therefore, lowering the threshold for NK cell activation is a promising approach to enhance their antitumor function.

Activation and inhibitory signaling in lymphocytes is fine-tuned through intracellular checkpoints, such as E3 ubiquitin ligases. Members of the Casitas B-lineage lymphoma pro-oncogene ligase family negatively regulate the activation of various lymphocyte subsets through targeted ubiquitination of intracellular signaling molecules, including protein tyrosine kinases.¹⁸ Ubiquitination of proteins triggers their localization to lysosomes or proteasomes for degradation, thus negatively regulating the initiation and progression of immune responses.^{19,20} Casitas B-lineage lymphoma pro-oncogene-b (CBLB) interacts with its specific targets via phosphotyrosine-containing sequence motifs that are generated on activated protein tyrosine kinases that mediate activating signal transduction.^{21,22} CBLB broadly regulates T-cell function^{23,24} through the inhibition of the PI3K pathway,²⁵ reduction of the linker for activation of T cells (LAT) phosphorylation and activation of PLC- γ 1,²⁶ negative regulation of Vav1 phosphorylation,²³ and induces partial resistance to transforming growth factor beta-mediated suppression.²⁷ Similarly, CBLB is a negative regulator of NK cell function. In NK cells, CBLB is activated and stabilized through inhibitory receptor signaling and reduces NK cell degranulation and cytotoxicity by targeted degradation of the adaptor protein LAT, which is involved in the recruitment of PLC- γ 1/2 to the immunological synapse between an NK cell and a target cell.^{28,29}

CBLB is induced in primary human NK cells by interleukin (IL)-15/IL-2 stimulation, interaction with K562 target cells³⁰ or by signaling via the inhibitory receptor KIR2D1.²⁸ Downregulation of CBLB in primary human NK cells significantly increased granzyme B (GZMB) and perforin expression, interferon gamma production and cytotoxicity against leukemia cell lines.³⁰ Knockdown of CBLB in a human NK cell line NKL showed higher cytotoxicity against the Jurkat cell line and improved in vivo anticancer activity, effectively mitigating lung metastasis in a murine melanoma model through the release of an inhibitory effect on TAM receptors.²¹ *Cblb* knockout (KO) rendered mouse NK cells less susceptible to programmed death-ligand 1 (PD-L1)-mediated inhibition³¹ and enhanced responsiveness to cytokine stimulation.³² Thus, the deletion of *CBLB* is an attractive strategy to lower the threshold for activation and enhance the antitumor function of NK cells.

We have developed a good manufacturing practice procedure for generating human placental CD34⁺ cell-derived NK (PNK) cells with substantial cytolytic activity against several human tumor cell lines.³³ PNK-007, a freshly formulated drug product, showed a high safety profile in phase I studies in patients with acute myeloid leukemia (AML) and multiple myeloma (MM) (Giarritta *et al*, manuscript in preparation)^{34–37}. We hypothesize that the anti-tumor function of PNK cells can be further

augmented by lowering their activation threshold by genetic deletion of negative regulators. Here, we demonstrate an effective use of CRISPR/Cas9 technology to genetically modify placenta-derived CD34⁺ hematopoietic stem cells and show that knocking out *CBLB* enhances the antitumor activity of PNK cells against several tumor cell lines and primary tumor cells. These data suggest that the deletion of negative regulators, such as *CBLB* in PNK cells, is a promising approach for developing more efficacious NK cell therapies for cancer.

MATERIALS AND METHODS

Placenta CD34⁺ cell isolation and culture

Placental CD34⁺ cells were acquired from healthy donors under fully informed consent. With donor eligibility documentation, tissues were qualified using a series of tests including serology and bacteriology (Lifebank USA). Blood was isolated from healthy donor tissues and processed by red blood cell depletion using Hetastarch (Hospira). The resulting cells were then magnetically labeled using Direct CD34 Progenitor Cell Isolation Kit (Miltenyi Biotec). CD34⁺ cells were positively selected using AutoMACS Cell Separator following manufacturer's protocol. Placental CD34⁺ cells were then cryopreserved in CryoStor CS10 (Biolife Solutions) and stored in liquid nitrogen before use.

For PNK culture, placental CD34⁺ cells were thawed and cultivated following a three-stage process in the presence of cytokines, including thrombopoietin, SCF, Flt3 ligand, IL-7, IL-15 and IL-2 (Thermo Fisher Scientific), for 35 days to generate PNK cells. Nucleofection of CRISPR reagents was performed at day 5–7 of culture. Cell count and passage were performed every 2–3 days and cell expansion was recorded. At the end of the culture, cell phenotype was evaluated by flow cytometry to confirm that the cells expressed typical NK receptors and cytolytic markers.

Immunophenotypal characterization

The phenotype of PNK cells was analyzed by multicolor flow cytometry. First, PNK cells were washed and stained with fluorochrome-conjugated antibodies diluted in staining buffer (10% fetal bovine serum in phosphate-buffered saline (PBS)) according to the manufacturer's instructions. CD244 (clone: 2B4)—FITC (BD Biosciences), CD226 (DNAM-1) (clone: DX11)—PE (Miltenyi Biotec), CD94 (clone: HP-3D9)—PerCP-Cy5.5 (BD Biosciences), CD314 (NKG2D) (clone: 1D11)—APC (Miltenyi Biotec), CD56 (clone: NCAM16.2)—Pe-Cy7 (BD Biosciences), CD3 (clone: SK7)—APC-H7 (BD Biosciences), CD14 (clone: M ϕ P9)—APC-H7 (BD Biosciences), CD19 (clone: HIB19)—APC-Cy7 (BD Biosciences), CD69 (clone: FN50)—AF700 (BD Biosciences), NKp46 (CD335) (clone: 9E2)—BV650 (BD Biosciences), TIGIT (clone: A15153G)—BV605 (Biolegend), CD336 (NKp44) (clone: p44-8)—BUV395 (BD Biosciences), CD337 (NKp30) (clone: p30-15)—BV421 (BD Biosciences),

Figure 1 Efficient CRISPR/Cas9-mediated *CBLB* gene editing and conserved NK cell identified in human PNK cells. (A) representative growth curves of *CBLB* KO PNK cell cultures. *Cas9* mRNA and *CBLB* gRNA were introduced by transfection on day 5 (n=3). (B) Quantification of Ctrl or KO PNK cell expansion at day 35 of PNK culture, mean±SD (n=3). (C) *CBLB* gene editing efficiency using tide analysis summarizing eight individual experiments after transfection and on days 34–35 of PNK cell culture. Gene editing efficiency is determined as the frequency of nucleotide additions or deletions, mean±SD (n=8). (D) Western blot analysis of *CBLB* protein in day 35 Ctrl and KO PNK cells. β -actin serves as a loading control (n=3). (E) Representative dot plot of PNK cell gating. Indicated population was first gated of live single cells (not shown). Lins were CD3, CD14 and CD19. (F) Quantification of $\text{Lin}^- \text{CD56}^+$ cells in Ctrl and KO PNK cell cultures, mean±SD (n=3). (G) Representative histograms demonstrating the expression of indicated NK cell markers in Ctrl (white dashed) and KO PNK (gray) cells on day 35 of culture. KIR=CD158e1/e2 and CD158b1/b2,j. Vertical dotted line marks isotype control. (H) Quantification of the expression of indicated NK cell markers on Ctrl and KO cells, mean±SD (n=3). **P<0.01. *CBLB*, Casitas B-lineage lymphoma pro-oncogene-b; Ctrl, control; KIR, killer Ig-like receptor; KO, knockout; Lin, lineage marker; NK, natural killer; PNK, placental CD34⁺ cell-derived NK; PERP, perforin.

CD11a (clone: HI111)—BV711 (BD Biosciences), CD16 (clone: 3G8)—BV786 (BD Biosciences), CD158a (clone: HP-3E4)—PE (BD Biosciences), CD158e1/e2 (clone: Z27.3.7)—PE (Beckman Coulter), CD158b1/b2,j (clone:

GL183)—PE (Beckman Coulter), CD159a (NKG2A) (clone: 3D12HLA-E)—APC (Thermo Fisher Scientific), GZMB (clone: X40)—AF700 (BD Biosciences), perforin (clone: dG9)—BV421 (BD Biosciences), TIM-3 (CD366)

Figure 2 *CBLB* KO PNK cells demonstrate enhanced cytotoxicity against hematological cancer and solid tumor lines in vitro. The efficacy of tumor cell cytotoxicity was analyzed in *CBLB* KO and their corresponding Ctrl cells in a 4-hour in vitro cytotoxicity assay against RPMI8266 (A), ARH77 (B) and U266 (C) cell lines using E:T ratios of 20:1, 10:1 and 5:1. The proportion of dead target cells was quantified by flow cytometry. The figures next to the curves indicate lytic units (LU₂₀/10⁶ cells), mean±SD (n=3). (D,E) Cytotoxicity of Ctrl and KO PNK cells against of an adherent cancer cell line U-251 MG from three donors at an E:T ratio of 2.5:1 analyzed using an impedance-based RTCA platform. Cytotoxicity against U-251 MG over 24 hours (D) and at a 4-hour time point (E) (n=3). *P<0.05, ****P<0.0001. *CBLB*, Casitas B-lineage lymphoma pro-oncogene-b; Ctrl, control; E:T, effector-to-target; KO, knockout; PNK, placental CD34⁺ cell-derived NK; RTCA, real time cytolytic assay.

(clone: F38-2E2)—BV605 (Biolegend). Dead cells were labelled with the Live/Dead Fixable Aqua Stain (Thermo Fisher Scientific) and gated out. For intracellular staining, surface-stained cells were permeabilized using the Fixation/Permeabilization Solution Kit (BD Biosciences) according to manufacturer's recommendations and stained with fluorochrome-conjugated antibodies recognizing intracellular molecules. Stained cells were acquired on BD Fortessa X20 flow cytometer (BD Biosciences) and data were analyzed using FlowJo software.

Gene editing by CRISPR/Cas9

CBLB guide RNAs (gRNA) were designed using an online design tool from the Zhang lab at Massachusetts Institute of Technology (<http://crispr.mit.edu/>). The gRNA sequence of TAATCTGGTGGACCTCATGAAGG was selected. gRNA with 2'-O-methyl 3'phosphorothioate modifications incorporated in the three terminal nucleotides at both the 5' and 3' ends were custom-ordered from TriLink Biotechnologies. Cas9 messenger RNA (mRNA), which is capped using antireverse cap analog (Cap 0), polyadenylated and modified with 5-methylcytidine and pseudouridine (5meC, Ψ), was produced by TriLink.

Transfection of PNK cells

At days 5–7 of culture, transfection with Cas9 mRNA and *CBLB* gRNA (TriLink BioTechnologies) was conducted using the Lonza Nucleofector and the Human CD34⁺ Cell Nucleofector Kit (Lonza) according to manufacturer's protocol. Briefly, 15 μg of Cas9 mRNA and 15 μg of *CBLB* gRNA were transfected into 2×10⁶ cells in a 100 μL volume. After transfection, cells were transferred to PNK culture media at a density of 200,000/mL. For the control

group, cells were either not transfected or transfected with only 15 μg of Cas9 mRNA.

Tracking of indels by decomposition (TIDE) assay

Gene editing efficiency was determined by TIDE analysis at days 12–14 and at the end of the PNK culture. Briefly, cells were lysed with Quick Extract buffer (Thermo Fisher Scientific). *CBLB* gene specific primers 5'-TGAT AGCCTAGGACTGTTTGAGAGAA-3' (forward) 5'-CCAG GCTCACAGCATCTGATAAC-3' (reverse) were used to amplify *CBLB* genomic region by PCR. PCR samples were sequenced using the Sanger method and analyzed using the TIDE web tool (<https://tide.nki.nl/>).³⁸

Western blot

To determine the efficiency of *CBLB* deletion at the protein expression level, mature PNK cells were lysed in radioimmunoprecipitation assay (RIPA) Lysis and Extraction Buffer (Thermo Fisher Scientific) including 1× Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific). Clarified cell lysates were separated on Novex Tris-Glycine Mini Gels (Thermo Fisher Scientific) by electrophoresis, and the total protein was transferred to a polyvinylidene difluoride (PVDF) membrane (Thermo Fisher Scientific). The membrane was blocked with Superblock T20 Blocking Buffer (Thermo Fisher Scientific) and incubated overnight at 4°C with rabbit anti-*CBLB* (Cell Signaling Technologies, clone: D3C12) diluted at 1:500 and mouse anti-β-Actin (Cell Signaling Technologies, clone: 8H10D10) diluted at 1:2000 in blocking buffer. After washing, the membrane was incubated for 1 hour at room temperature with IRDye 680RD donkey anti-mouse (LI-COR Biosciences) and

Figure 3 Biodistribution and persistence of *CBLB* KO PNK cells in vivo. (A) Schematic of experimental procedures for in vivo biodistribution and proliferation studies. *CBLB* KO or Ctrl PNK cells were injected intravenously into NSG mice 1 day after intraperitoneal busulfan treatment. rhIL-15 was administered intraperitoneally every 2 days until day 12. Animals were sacrificed on days 3, 7, 14 and 21 for analysis of PNK cells using hCD45 staining ($n=4-5$). (B) Quantification of hCD45⁺ cell numbers quantified in blood, BM, liver, lungs and spleen on days 7, 14 and 21 after infusion of Ctrl or *CBLB* KO PNK cells. (C) Quantification of hCD45⁺ cells in indicated organs on day 14 after PNK cell infusion, mean $\pm$ SD ($n=5$). (D) CFSE-labeled Ctrl or *CBLB* KO PNK cells were injected intravenously in NSG mice, and animals were sacrificed on days 3, 7, 14 or 21 to analyze CFSE signal on PNK cells. Each histogram represents data from one mouse ($n=4$). (E,F) Proportion of PNK cells isolated from the liver (E) or the lungs (F), expressing the proliferation marker Ki67. (G) Quantification of indicated NK cell surface receptors on Ctrl or *CBLB* KO PNK cells after harvested from mice. Day 0 sample represents the preinfusion phenotype. * $P<0.05$, ** $P<0.01$, *** $P<0.001$, **** $P<0.0001$. BM, bone marrow; CBLB, Casitas B-lineage lymphoma pro-oncogene-b; CFSE, carboxyfluorescein succinimidyl ester; Ctrl, control; h, human; IL, interleukin; KO, knockout; NK, natural killer; NSG, NOD-*scid* IL2R gamma^{null}; PNK, placental CD34⁺ cell-derived NK.

IRDye 800CW donkey anti-rabbit (LI-COR Biosciences) at 1:15 000 in blocking buffer. The membrane was imaged using LiCOR CLx Imager (LI-COR Biosciences).

In vitro cytotoxicity assay

RPMI8226, U266, ARH77, HL-60, K562, KG1 and U251 MG cell lines were purchased from American Type Culture Collection (ATCC) and cultured following ATCC recommendations. For cytotoxicity against RPMI8226, U266, ARH77, K562, KG1 and HL-60, target cells were

washed with PBS and labeled with PKH26 (Sigma-Aldrich) according to manufacturer's protocol. *CBLB* KO PNK or control cells were cultured together with PKH26-labeled target cells in 96-well U-bottom plates at different effector-to-target (E:T) ratios for 4 hours.³⁹ TO-PRO-3 (Thermo Fisher Scientific) was added at the end of the 4-hour culture at 0.25 μ M concentration for 20 min, followed by flow cytometric analysis. Cytotoxicity was expressed as the percentage of dead cells (PKH26⁺

Figure 4 *CBLB* KO PNK cells reduce tumor burden in vivo. (A) Schematic of experimental procedures for the evaluation of antitumor activity of Ctrl or *CBLB* KO PNK cells in vivo using HL-60 xenograft mouse model ($n=6-7$). One day after busulfan treatment, 1×10^5 HL-60 cells expressing luciferase were injected intravenously to NSG mice and NK cells were injected on days 2 and 7 post-tumor cell injection to three randomized animal groups (PBS, Ctrl PNK or *CBLB* KO PNK cells). Each animal received 1×10^7 cells. rhIL-15 was administered intraperitoneally every 2 days until day 20. (B) Representative bioluminescence imaging of each group shows the tumor burden at days 6, 9, 13, 16 and 20. All animals were sacrificed at day 21. (C) Tumor burden of each group normalized to PBS Ctrl group as tumor growth fold change. (D) Survival plot of the HL-60 xenograft mouse administered with PBS, Ctrl or *CBLB* KO PNK cells. Asterisks (*) indicate significant difference between Ctrl and KO groups compared with the PBS group. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$. *CBLB*, Casitas B-lineage lymphoma pro-oncogene-b; Ctrl, control; IL, interleukin; KO, knockout; NK, natural killer; NSG, NOD-*scid* IL2R gamma^{null}; PBS, phosphate-buffered saline; PNK, placental CD34⁺ cell-derived NK; rh, recombinant human.

TO-PRO-3⁺) within the total PKH26⁺ target tumor cells. Lytic units (LU₂₀/10⁶ cells) were calculated as follows: % of specific lysis (Y axis) was plotted in function of E:T ratio (log scale X axis) and linear regression calculated. E:T value for 20% cytotoxicity (E:T₂₀) was derived from the trendline. Lytic units were calculated based on the equation $LU_{20}/10^6 \text{ cells} = 10^6 \times ((E:T_{20}) \times T_{\text{well}})^{-1}$, where T_{well} is target cell number per well.⁴⁰ Cytotoxicity against solid tumor cells (U251) was measured using the xCELLigence RTCA platform (ACEA Bioscience). U251 were cultured in 96-well electronic microtiter plates overnight, followed by addition of PNK cells at an E:T ratio of 2.5:1. Cell index, indicating the impedance of electron flow caused by adherent cells, was recorded real time. Percentage of cytotoxicity was calculated using the formula provided by ACEA Bioscience: (cell index of no effector-cell index of effector)/cell index of no effector $\times 100$.

Animal studies

Animal studies were conducted by a contract research organization accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, and studies were approved by the Institutional Animal Care and Use

Committee. The studies were performed on female NOD-*scid* IL2R gamma^{null} (NSG) mice, 8 weeks old, approximately 18–22 g at study initiation.

In vivo biodistribution and persistence

In vivo distribution and persistence of *CBLB* KO PNK cells were evaluated relative to control cells transduced with Cas9 mRNA (control) in NSG mice. Specifically, NSG mice were pretreated with 30 mg/kg busulfan (Alfa Aesar) at day -1. The next day, 1×10^7 *CBLB* KO PNK or control cells were intravenously injected via the tail vein. Recombinant human (rh)IL-15 (Thermo Fisher Scientific) was given via intraperitoneal injection at 0.5 $\mu\text{g}/\text{mouse}/\text{day}$ every 2 days from day 0 to day 12. Animals ($n=4-5$) from each group were sacrificed at days 7, 14, and 21. At each time point, peripheral blood, bone marrow, lungs, liver and spleen were harvested. Lungs, liver and spleen were dissociated into single-cell suspensions using the gentleMACS Dissociator (Miltenyi Biotec) according to manufacturer's instructions. Single-cell suspensions from all other tissues were filtered through 100 μm nylon filters and centrifuged. Red blood cells were lysed using ACK lysis buffer (Gibco). By flow cytometry, PNK cells were subsequently quantified by the amount of human CD45⁺

cells in peripheral blood, bone marrow, lungs, liver, and spleen samples.

In vivo proliferation and maturation

To evaluate cell proliferation in vivo, PNK (*CBLB* KO or control) cells were labeled with carboxyfluorescein succinimidyl ester (CFSE) dye at day 35 of culture and infused into NSG mice (n=4). Cell labeling was performed using CellTrace CFSE Cell Proliferation Kit (Thermo Fisher Scientific) according to the manufacturer's instructions. CFSE labeled PNK cells were intravenously administered in busulfan preconditioned NSG mice at a dose of 1×10^7 cells/mouse. rhIL-15 was given intraperitoneally at 0.5 μ g/mouse/day every 2 days from days 0 to 12. After 3, 7, 14 and 21 days of infusion, mouse liver was harvested and dissociated into single cell suspension as described previously. CFSE was analyzed by flow cytometry to characterize PNK cell proliferation in vivo. Additionally, in a separate study with the same design, unlabeled PNK cells were infused into busulfan preconditioned mice (n=5). On days 3, 7, 14 and 21 after infusion, cells were harvested from the peripheral blood, bone marrow, lungs, liver and spleen as described previously, and were analyzed for cell proliferation marker Ki67 (clone: B56)—PE (BD Biosciences) by flow cytometry. Cells harvested from the mouse livers were analyzed for human NK cell maturation markers CD11a, CD16, killer Ig-like receptors (KIRs), and NKG2A by flow cytometry.

In vivo antitumor efficacy

Antitumor activity of PNK cells was evaluated in a Xenograft AML model in NSG mice. To establish the model, HL-60 cells were transduced with a lentiviral construct (Amsbio) to express green fluorescence protein and luciferase. Cells were sorted for the top 2.5% expressors using FACS Aria flow cytometer (BD) and were used for the animal study. Specifically, 1×10^5 HL-60 cells expressing luciferase were inoculated intravenously to NSG mice at day 0 after busulfan preconditioning (day -1). At days 2 and 7, 1×10^7 *CBLB* KO (n=7) or control (n=7) PNK cells were injected intravenously and PBS was used as the non-treatment control. rhIL-15 was given intraperitoneally at 0.5 g/mouse/day every 2 days from days 2 to 20. Tumor growth was measured by in vivo bioluminescence imaging twice weekly starting from day 2. Mouse body weight was measured every 4 days until study termination at day 20.

Statistical analysis

Experimental data were graphed and analyzed with Prism. All data were presented as mean $\pm$ SD. For in vitro expansion and phenotype data, paired t-test was performed to determine the difference between *CBLB* KO and control groups. For in vitro cytotoxicity data and in vivo data, two-way analysis of variance was first performed, and then a pairwise comparison was made. Log-rank test was used to compare survival curves between groups. A p value of ≤ 0.05 is considered significant. An asterisk

indicates significance: *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001; no asterisk indicates no statistical significance.

RESULTS

As *CBLB* acts as an important gatekeeper limiting NK cell cytotoxicity in various tumor models,²¹ we used CRISPR/Cas9 technology to generate *CBLB* KO PNK cells to enhance their cytotoxic potential. PNK cells are generated from placenta-derived CD34⁺ stem cells following a 35-day culture process. To generate *CBLB* KO PNK cells, placenta-derived CD34⁺ cells were transfected with *CBLB* guide RNAs and Cas9 mRNA on day 5 of culture. Control cells only received Cas9 mRNA. To evaluate the possible effect of transfection on CD34⁺ cell culture, we monitored their expansion over the 35-day culture process (figure 1A). The fold expansion of three independent gene modification experiments was analyzed. Both *CBLB* KO and control cells resulted in an average of >2000-fold expansion by the end of the 35-day culture process with no difference between treatment conditions (figure 1B). A growth arrest of 2–3 days was observed after electroporation at day 5, likely due to the transfection event. The cells quickly recovered, demonstrating a fast and steady expansion from days 7 to 25, and thereafter reached a plateau until harvest on day 35. The data suggest that *CBLB* deletion does not affect CD34⁺ cell proliferation and differentiation towards PNK cells. Gene editing efficiency was evaluated on culture days 12–14 and 34–35 using the TIDE assay.³⁸ A high *CBLB* editing efficiency was achieved: 85% (range 78%–95%) on days 12–14 and 94% (range 84%–99%) on days 34–35 (figure 1C). Successful *CBLB* deletion was confirmed by a lack of *CBLB* protein detected by Western blot in gene-edited PNK cells on day 35 of culture (figure 1D). A strong protein band was detected at 125 kDa only in non-modified control cells corresponding to the expected size of the *CBLB* protein. The data show that complete ablation of *CBLB* protein in PNK cells was achieved with high efficiency by genetic modification of CD34⁺ stem cells using CRISPR/Cas9 technology.

To confirm that CRISPR/Cas9-mediated gene modification did not affect the differentiation of PNK cells, we used flow cytometry to immunophenotype *CBLB* KO PNK cells and donor-matched control cells harvested on day 35. *CBLB* gene modification did not affect PNK cell purity, indicated by >95% of CD56⁺ cells that lacked T cell, B cell or monocyte markers CD3, CD19 or CD14, respectively (figure 1E,F). We next performed comprehensive characterization of *CBLB* KO PNK cells to eliminate any effect of *CBLB* deletion on their receptor profile and activation potential. Similarly to control cells, *CBLB* KO PNK cells demonstrated high CD56, minimal CD16, and no killer Ig-like receptor (KIR) expression, consistent with a phenotype for NK cells differentiated from hematopoietic stem cell precursors (figure 1G,H).⁴¹ NK cell proteins that mediate target recognition (Nkp30, Nkp44, Nkp46,

NKG2D, DNAM-1, NKG2A, and CD94), formation of the immunological synapse (CD11a) and cytotoxic response (GZMB and perforin) were expressed on both control and *CBLB* KO PNK cells. There was no significant change in the expression of any of these markers comparing *CBLB* KO to control PNK cells, suggesting that *CBLB* ablation did not affect the differentiation and maturation of PNK cells during cultivation.

We have previously demonstrated that PNK cells exhibit cytotoxicity against a wide range of tumor cell lines.³³ To evaluate the effect of *CBLB* ablation on PNK cell effector functions, we first tested their cytotoxicity in vitro. The cytolytic activity of *CBLB* KO PNK cells was evaluated in a flow cytometry-based cytotoxicity assay against myeloma cell lines RPMI8226 and U266, and plasma cell leukemia cell line ARH77 (figure 2A–C). Significantly higher cytotoxicity of *CBLB* KO PNK cells was observed against tumor cell lines at every E:T ratio tested compared with non-modified control cells from the same donor. We also used an impedance-based cytotoxicity assay to analyze the cytotoxicity of *CBLB*-deficient PNK cells against the U-251 MG glioblastoma cell line. *CBLB* KO cells showed improved relative killing activity over control cells during a 24-hour period (figure 2D,E). *CBLB* deletion improved overall cytotoxicity of PNK cells against liquid and solid tumor cell lines in vitro.

Clinical studies have suggested that persistence and expansion of donor NK cells are required to show efficacy of NK cell therapy.⁴² Therefore, we first examined the persistence and biodistribution of *CBLB* KO and control cells in lymphocyte-deficient NSG mice. Ten million *CBLB* KO or control cells were injected into busulfan-treated (day –1) NSG mice via the tail vein (figure 3A). rhIL-15 was given intraperitoneally every 2 days until day 12. Animals were sacrificed at different time points to analyze PNK cell persistence using anti-hCD45 staining and flow cytometry. Infused PNK cells, characterized by hCD45⁺ expression, were detected in all tissues examined, including peripheral blood, bone marrow, spleen, lungs and liver of mice on days 7, 14 and 21 (figure 3B,C). hCD45⁺ cell number in blood and the tissues analyzed increased from days 7 to 14, but significantly dropped by day 21 (figure 3B). Importantly, hCD45⁺ cell counts were comparable in animals receiving either *CBLB* KO or control PNK cells for the first 2 weeks. Figure 3C shows a representative PNK cell distribution in all tissues examined (day 14 time point), with the highest cell number found in the liver and the lungs. Control and *CBLB* KO PNK cells were found to have similar biodistribution in mice with comparable numbers for all organs analyzed. These data demonstrate that *CBLB* deficiency does not affect the biodistribution and persistence of PNK cells in vivo.

NSG mice infused with PNK cells were treated with rhIL-15 to promote PNK cell proliferation and persistence. We evaluated the proliferation of *CBLB* KO and control cells by administering CFSE-labeled PNK cells to NSG mice according to the protocol described in

figure 3A. hCD45⁺ cells harvested from the mouse liver were analyzed for the intensity of CFSE signal by flow cytometry on different days postinjection. CFSE intensity decreased from days 3 to 21 in both the control and *CBLB* KO PNK cells, indicating cell proliferation in vivo (figure 3D). Additionally, reduced and rapidly decreasing CFSE signal, indicating increased proliferation, was detected in *CBLB* KO cells compared with control PNK cells (figure 3D). We also analyzed the proliferation marker Ki67 expression on *CBLB* KO and control PNK cells in different tissues (figure 3E,F and online supplemental figure 1). An increase of in vivo proliferation of *CBLB* KO PNK cells was detected in the liver and the lungs on days 3 and 7 (figure 3E,F). PNK cell numbers in tissues (figure 3B) and Ki67 expression (figure 3E,F) correlated with the rhIL-15 infusion period (figure 3A), demonstrating a significant role of IL-15 on NK cell proliferation and persistence.

In vitro cultured NK cells further mature in vivo and acquire a phenotype resembling peripheral blood NK cells.⁴¹ To characterize PNK cell phenotype after infusion to NSG mice, the expression of surface markers representing the differentiation and maturation of NK cells, including CD11a, CD16, NKG2A and KIR, were analyzed on hCD45⁺ cells in the liver (figure 3G). In both *CBLB* KO and control cells, all four markers increased from days 3 to 21 after infusion compared with preinfusion cells, suggesting that PNK cells underwent further maturation in vivo and that *CBLB* ablation did not impair this process. *CBLB* KO cells, however, showed significantly higher KIR expression on days 14 and 21 compared with control cells, suggesting that the ablation of *CBLB* resulted in enhanced PNK differentiation in vivo.

Next, we evaluated if the in vivo infused PNK cells maintained their cytolytic potential and analyzed the cytotoxicity of *CBLB* KO and control PNK cells ex vivo against myeloid leukemia cell lines K562, HL-60 and KG1. The results confirmed that *CBLB* KO cells isolated from mice demonstrated enhanced cytotoxicity against all three cell lines compared with control cells (online supplemental figure 2).

To analyze whether elevated in vitro cytotoxicity and higher in vivo proliferation and maturation of *CBLB* KO PNK cells translated into enhanced in vivo antitumor efficacy, we established a human AML cell line HL-60 xenograft in the NSG mouse (figure 4A). HL-60 cells expressing luciferase were injected at 1×10^5 intravenously into NSG mice (day 0), followed by 1×10^7 *CBLB* KO or control PNK cells on days 2 and 7. Non-treated control mice were injected with PBS. Both *CBLB* KO and control PNK cell-treated mice showed significantly less tumor burden between days 6 and 16 compared with PBS-treated control animals that were all sacrificed between days 17 and 19 due to aggressive progression of the tumor. *CBLB* KO PNK cells showed significantly improved control of the tumor compared with control PNK cells from days 9 to 21 (figure 4B,C). Although there was significant reduction in tumor burden in mice receiving *CBLB* KO cells

compared with control cells, this difference did not translate into a survival benefit. However, animals that received control or CBLB KO PNK cells lived longer than PBS-treated control mice (figure 4D).

DISCUSSION

Novel immunotherapies for cancer are rapidly changing the way tumors are treated in the clinic. Major advancements have recently been made in the development and successful application of monoclonal antibodies and engineered immune cells. While the introduction of tumor-specific CAR T cells for autologous cell therapy has demonstrated striking results against hematological malignancies, CAR T cell therapies still face many challenges, which include high cost, a long manufacturing process and issues associated with autologous approaches. NK cells are cytotoxic innate immune cells that use an array of universal receptors, which recognize markers of oncogenic transformation on malignant cells and therefore require no prior sensitization for target identification. The safety and clinical effectiveness of adoptive NK cell therapy have been shown in multiple clinical studies using ex vivo activated and/or expanded NK cells derived from various sources.⁴³ For these properties, NK cells are actively investigated as an attractive alternative to CAR T cells in multiple ongoing clinical trials targeting hematological or solid tumors.⁴⁴ Ex vivo activation, expansion, and genetic modification can further enhance NK cell cytotoxic potential and overcome resistance of tumor cells to NK cell recognition and killing.

In this study, we established a process to produce genetically modified NK cells with improved cytotoxic function using CRISPR/Cas9 gene editing technology. By knocking out *CBLB* gene in CD34⁺ hemopoietic stem cells derived from full-term postpartum human placenta, we significantly improved the cytotoxic function of placental CD34⁺ cell-derived NK (PNK) cells in vitro and in vivo. It is widely recognized that the E3 ligase CBLB is a central player in the negative regulation of lymphocyte function, including NK cells, and was therefore selected for deletion in this proof-of-concept study.¹⁸ Our data demonstrate that CBLB is a negative regulator of PNK cell function and that genetic manipulation of placental CD34⁺ cells is a feasible approach to enhance antitumor cytotoxicity for immunotherapy.

CBLB gene modification of CD34⁺ cells did not result in any obvious developmental or phenotypical defects in PNK cells, as we achieved greater than 95% of the cells expressing CD56 and other NK cell prototypic markers at a comparable level to non-modified cells. This agrees with a previous report that *CBLB* KO mice develop NK cells normally.²¹ In vivo, PNK cell numbers, their proliferation and maturation correlated with rhIL-15 treatment period, highlighting the key role of IL-15 cytokine on NK cell persistence and homeostasis. We observed increased proliferation of CBLB KO cells compared with unmodified PNK cells in vivo, similarly to what has been observed

by others.²¹ The increased in vivo proliferation of CBLB KO PNK cells could partially explain the reduced tumor burden in mice treated with the CBLB KO cells.

Phenotypically, PNK cells, either unmodified or CBLB KO, are of CD56^{bright} CD16⁻ phenotype that is considered to be more immature compared with the CD56^{dim} CD16⁺ NK cells in the blood.⁴⁵ PNK also show lower expression of the inhibitory KIRs but increased expression of the activating NKp30, NKp44 and NKp46 receptors, similar to reports by others for CD34⁺ cell-derived NK cells.⁴⁶ In vivo, PNK cells demonstrated rapid maturation, illustrated by the upregulation of CD16, CD11a and KIRs, a phenotype that is associated with increased cytotoxicity.⁴⁵

CBLB ablation in PNK cells increased cytotoxicity against tumor cells both in in vitro and in vivo models. This is in accordance with recent studies from Lu *et al* demonstrating significantly increased cytotoxicity of primary human NK cells on knockdown of CBLB.³⁰ Increased cytotoxicity of *CBLB* KO PNK over control cells appears to be comparable to previously reported murine *CBLB* KO NK cells over their wild-type counterparts,²¹ suggesting a conserved role of CBLB in the regulation of NK cell cytotoxicity in mice and men. The in vivo study showed that PNK cells significantly reduced tumor (HL-60) burden in mice and that *CBLB* deficiency further enhanced PNK cytotoxicity and reduced tumor burden compared with control cells. Although there was no survival benefit when using *CBLB* KO PNK cells versus control cells, it is possible that the decrease in tumor burden mediated by *CBLB* KO in PNK cells was not sufficient to confer a survival benefit in this aggressive tumor model using the HL-60 cancer cell line that leads to 100% of lethality in mice within 3 weeks.

In conclusion, we have established a process to generate clinical-grade PNK cells for immunotherapy of various cancers or infectious disease, and we demonstrated the feasibility of using genetic modification by CRISPR/Cas9 technology to enhance their antitumor function. CBLB, a negative regulator of NK cell function, was selected as a target for deletion. While a high KO efficiency was achieved, CBLB deletion did not affect CD34⁺ cell proliferation or differentiation into PNK cells. Furthermore, CBLB deletion enhanced proliferative capacity and effector function of PNK cells in vivo. Altogether, the data suggest that genetic modification is a promising approach to further enhance NK cell persistence and antitumor potential for the purpose of offering therapeutic advantages in cancer immunotherapy.

Acknowledgements We thank Tianjian Li, Chuan Wang, Mini Bharathan and Vladimir Jankovic for their scientific contributions to the article.

Contributors XG, QY, SS, SH, RH and XZ conceptualized the study. RH and XZ acquired funding. XG, TM, QY, SS, SH, WvdT, RH and XZ led the study and provided supervision. XG, TM, SS, HR, QY, SH, AD and JG conducted experiments and analyzed the data. XG, QY and SS prepared the first draft of the manuscript. TM, QY, TM, XG, SS and SH wrote the manuscript. All authors contributed to the review and editing of the manuscript and approved the final version.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No data are available. All data relevant to the study are included in the article or uploaded as supplementary information. Data are available upon reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Tanel Mahlaköiv <http://orcid.org/0000-0001-9059-0486>

REFERENCES

- Shimasaki N, Jain A, Campana D. Nk cells for cancer immunotherapy. *Nat Rev Drug Discov* 2020;19:200–18.
- Carlsten M, Childs RW. Genetic manipulation of NK cells for cancer immunotherapy: techniques and clinical implications. *Front Immunol* 2015;6:266.
- Vivier E, Tomasello E, Baratin M. Functions of natural killer cells. *Nat Immunol* 2008.
- Romanski A, Uherek C, Bug G, et al. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. *J Cell Mol Med* 2016;20:1287–94.
- Oelsner S, Waldmann A, Billmeier A, et al. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth. *Int J Cancer* 2019;145:1935–45.
- Liu E, Tong Y, Dotti G, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. *Leukemia* 2018;32:520–31.
- Xu Y, Liu Q, Zhong M, et al. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies. *J Hematol Oncol* 2019;12:49.
- Shimasaki N, Fujisaki H, Cho D, et al. A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. *Cytotherapy* 2012;14:830–40.
- Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. *Blood* 2005;106:376–83.
- Chu Y, Hochberg J, Yahr A, et al. Targeting CD20+ aggressive B-cell non-Hodgkin lymphoma by anti-CD20 CAR mRNA-modified expanded natural killer cells in vitro and in NSG mice. *Cancer Immunol Res* 2015;3:333–44.
- Jiang H, Zhang W, Shang P, et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. *Mol Oncol* 2014;8:297–310.
- Chu J, Deng Y, Benson DM, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. *Leukemia* 2014;28:917–27.
- Esser R, Müller T, Stefes D, et al. Nk cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. *J Cell Mol Med* 2012;16:569–81.
- Genblier S, Burger MC, Zhang C, et al. Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival. *Oncotarget* 2016;5:e1119354.
- Koh CY, Blazar BR, George T, et al. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. *Blood* 2001;97:3132–7.
- Koh CY, Ortaldo JR, Blazar BR, et al. Nk-cell purging of leukemia: superior antitumor effects of NK cells H2 allogeneic to the tumor and augmentation with inhibitory receptor blockade. *Blood* 2003;102:4067–75.
- Binyamin L, Alpaugh RK, Hughes TL, et al. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. *J Immunol* 2008;180:6392–401.
- Lutz-Nicoladoni C, Wolf D, Sopfer S. Modulation of immune cell functions by the E3 ligase Cbl-b. *Front Oncol* 2015;5:58.
- Welchman RL, Gordon C, Mayer RJ. Ubiquitin and ubiquitin-like proteins as multifunctional signals. *Nat Rev Mol Cell Biol* 2005;6:599–609.
- Bhoj VG, Chen ZJ. Ubiquitylation in innate and adaptive immunity. *Nature* 2009;458:430–7.
- Paolino M, Choidas A, Wallner S, et al. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. *Nature* 2014;507:508–12.
- Mohapatra B, Ahmad G, Nadeau S, et al. Protein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligases. *Biochim Biophys Acta* 2013;1833:122–39.
- Bachmaier K, Krawczyk C, Kozieradzki I, et al. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. *Nature* 2000;403:211–6.
- Paolino M, Thien CBF, Gruber T, et al. Essential role of E3 ubiquitin ligase activity in Cbl-b-regulated T cell functions. *J Immunol* 2011;186:2138–47.
- Fang D, Liu YC. Proteolysis-independent regulation of PI3K by Cbl-b-mediated ubiquitination in T cells. *Nat Immunol* 2001;2:870–5.
- Jeon M-S, Atfield A, Venuprasad K, et al. Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. *Immunity* 2004;21:167–77.
- Wohlfert EA, Gorelik L, Mittler R, et al. Cutting edge: deficiency in the E3 ubiquitin ligase Cbl-b results in a multifunctional defect in T cell TGF-beta sensitivity in vitro and in vivo. *J Immunol* 2006;176:1316–20.
- Matalon O, Barda-Saad M. Cbl ubiquitin ligases mediate the inhibition of natural killer cell activity. *Commun Integr Biol* 2016;9:e1216739.
- Matalon O, Fried S, Ben-Shmuel A, et al. Dephosphorylation of the adaptor LAT and phospholipase C-gamma by SHP-1 inhibits natural killer cell cytotoxicity. *Sci Signal* 2016;9:ra54.
- Lu T, Chen L, Mansour AG, et al. Cbl-B is upregulated and plays a negative role in activated human NK cells. *J Immunol* 2021;206:677–85.
- Fujiwara M, Anstadt EJ, Clark RB. Cbl-B deficiency mediates resistance to programmed death-ligand 1/programmed death-1 regulation. *Front Immunol* 2017;8:42.
- Lametschwandtner G, Sachet M, Haslinger I, et al. Cbl-B silenced human NK cells respond stronger to cytokine stimulation. *J Immunother Cancer* 2015;3.
- Kang L, Voskrianian-Berse V, Law E, et al. Characterization and ex vivo expansion of human placenta-derived natural killer cells for cancer immunotherapy. *Front Immunol* 2013;4:101.
- Cooley S, Hari P, McCloskey J. Abstract CT079: a phase I study of PNK-007, allogeneic, off the shelf NK cell in relapsed/refractory AML (NCT02781467) 2019.
- Holstein SA, Cooley SA, Hari P. Abstract CT108: a phase I study of PNK-007, allogeneic, off the shelf NK cell, post autologous transplant in multiple myeloma (NCT02955550) 2019.
- Koppiseti S, Balint C, Giarritta E, et al. PS1215 safety and tolerability of allogeneic, OFF-THE shelf placental natural killer cells (PNK 007) in phase 1 multiple myeloma and acute myeloid leukemia studies (NCT02955550 and NCT02781467). *Hemasphere* 2019;3:554.
- Holstein SA, Cooley S, Hari P, et al. Results of a phase I study of Pnk-007, allogeneic, off the shelf NK cell, post autologous transplant in multiple myeloma (NCT02955550). *Blood* 2019;134:4451.
- Brinkman EK, Chen T, Amendola M, et al. Easy quantitative assessment of genome editing by sequence trace decomposition. *Nucleic Acids Res* 2014;42:e168.
- Lee-MacAry AE, Ross EL, Davies D, et al. Development of a novel flow cytometric cell-mediated cytotoxicity assay using the fluorophores PKH-26 and TO-PRO-3 iodide. *J Immunol Methods* 2001;252:83–92.
- Mbitikon-Kobo F-M, Bonneville M, Sekaly R-P, et al. Ex vivo measurement of the cytotoxic capacity of human primary antigen-specific CD8 T cells. *J Immunol Methods* 2012;375:252–7.
- Cichocki F, Grzywacz B, Miller JS. Human NK cell development: one road or many? *Front Immunol* 2019;10:2078.
- Geller MA, Miller JS. Use of allogeneic NK cells for cancer immunotherapy. *Immunotherapy* 2011;3:1445–59.

- 43 Shin MH, Kim J, Lim SA, *et al.* Nk cell-based immunotherapies in cancer. *Immune Netw* 2020;20.
- 44 Liu E, Marin D, Banerjee P, *et al.* Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. *N Engl J Med* 2020;382:545–53.
- 45 Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. *Trends Immunol* 2001;22:633–40.
- 46 Yoon SR, Lee YS, Yang SH, *et al.* Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. *Bone Marrow Transplant* 2010;45:1038–46.